Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips (NYSE: PHG) announced expanded commercial availability of LumiGuide, the first real-time AI-enabled, light-based 3D navigation solution for image-guided therapy, across Europe and the United States, with commercial orders starting January 2026. LumiGuide uses Fiber Optic RealShape (FORS) to visualize guidewires and compatible catheters in 3D without continuous X-ray and integrates with the Azurion image-guided therapy platform. Philips cites clinical use in >2,000 procedures and a referenced single-center study reporting procedures up to 37% faster and up to 56% DAP reduction. LumiGuide has FDA clearance and CE marking.
Philips (NYSE: PHG) launched Verida, described as the world’s first detector-based spectral CT fully powered by AI, announced at RSNA 2025 on November 30, 2025. Verida integrates AI across acquisition and reconstruction to deliver higher spectral and conventional image quality, claims dramatic dose reduction, up to 45% energy savings, and reconstructs 145 images/sec enabling exams to appear in <30 seconds and up to 270 exams/day. Verida is CE-marked, 510(k) pending, and availability in select markets begins in 2026.
Royal Philips (NYSE: PHG) on November 30, 2025 unveiled BlueSeal Horizon, an industry-first helium-free 3.0T MRI platform presented at RSNA 2025. The platform pairs a 3.0T helium-free magnet (with 7 liters permanently enclosed) with AI-powered workflow and imaging tools.
Philips cites prior BlueSeal scale: >2,000 1.5T installs and >6 million liters of liquid helium saved (compared with prior-generation magnets). Key AI features announced include SmartSpeed Precise (up to 3x faster scans; up to 80% sharper images), SmartPlanning (automated planning in as little as 30 seconds), real-time scan preview powered by NVIDIA, and SmartReading for cloud-based reading and reporting.
Disclosure: BlueSeal Horizon is a work in progress, not available in any jurisdiction and not for sale in the USA; future availability is not ensured.
Royal Philips (NYSE: PHG) launched Philips Image Management 15 with a next-generation, zero-footprint web diagnostic viewer that delivers desktop-level radiology capabilities in a standard browser.
The viewer offers high-performance server-side rendering, advanced clinical tools, native integration with an interactive reporting module, AI tool interfaces, and optional on-premises or cloud deployment via Philips HealthSuite on AWS. It is offered as a SaaS solution and is available in the USA today for select customers, with broader regional expansion planned for 2026.
Royal Philips (NYSE: PHG) on November 19, 2025 announced an extended partnership with Cortechs.ai to integrate Cortechs.ai’s AI-enabled NeuroQuant quantitative neuroimaging analytics into Philips MR workflows.
The companies plan to embed brain volumetrics, lesion quantification and tumor tracking into Philips MR systems via the cloud-based Smart Reading environment to deliver automated, zero-click quantitative reports to clinicians, aiming to improve speed, reproducibility and diagnostic confidence while addressing radiology workforce pressures.
NeuroQuant is currently available on Philips Advanced Visualization Workspace; Smart Reading integration is a work in progress and not yet available in any jurisdiction.
Philips (NYSE: PHG) on November 17, 2025 introduced DeviceGuide, an AI-powered device-tracking solution on the EchoNavigator platform that assists physicians during minimally invasive mitral valve repair (M-TEER).
DeviceGuide combines live echo and X-ray to generate a real-time 3D model of the repair device, helping clinicians visualize device position and orientation inside the beating heart. It was developed with Edwards Lifesciences and will be previewed at London Valves 2025. Availability depends on local regulatory clearance and DeviceGuide is currently intended for use only with the Edwards PASCAL Ace mitral TEER device.
Philips (NYSE:PHG) reported Q3 2025 results showing continued momentum: comparable order intake +8%, group sales €4.3 billion (comparable sales +3.3%), and adjusted EBITA margin 12.3% (up 50 bps). Income from operations was €330 million. Free cash flow rose to €172 million and operating cash flow was €327 million. Productivity measures delivered €222 million of quarterly savings and the company remains on track for its three-year €2.5 billion productivity program.
Philips reiterated full‑year 2025 guidance, now expected toward the upper end of the adjusted EBITA margin range, and highlighted product launches, clinical trial results and sustainability validation by SBTi.
Philips (NYSE: PHG) announced support for the Forever Promise Project, an initiative connecting families of fallen World War II U.S. service members with Dutch adopters of graves at the Netherlands American Cemetery in Margraten.
Philips will help advance efforts to connect all 10,000 American families with Dutch adopters and offer employee volunteer opportunities to support remembrance activities and foster cross‑border relationships.
Hoag (partnering with Royal Philips, NYSE: PHG) announced a 10-year strategic collaboration to standardize and modernize patient monitoring across its two acute care hospitals and the expanded Sun Family Campus in Irvine, which will add 155 inpatient beds in mid-2026. Hoag will adopt Philips Enterprise Monitoring as a Service (EMaaS) and deploy IntelliVue MX750 bedside and X3 transport monitors plus the Philips Patient Information Center (PIC iX).
The integrated solution delivers continuous monitoring, early warning scores, analytics, and EHR interoperability to support clinical efficiency, patient safety and financial predictability for ongoing innovation access.
Royal Philips (NYSE:PHG) reported late-breaking 3-year results from the iMODERN trial (n=1,146) showing no significant difference in the primary composite endpoint (death, recurrent MI, or heart failure hospitalization) between immediate iFR-guided multivessel treatment during primary PCI and staged CMR-guided treatment within 4 days–6 weeks. Results were published in The New England Journal of Medicine and presented at TCT 2025. Complementary ILIAS ANOCA data (n=153) showed a sustained mean +9.4-point Seattle Angina Questionnaire gain at 6 months with ad-hoc coronary function testing and tailored therapy, with no procedure-related major events.